Denosumab and Atypical Femoral Fractures: A Scoping Literature Review

Ammar Ismail,1 Amira Hassan Bekhet,2 Abdelrahman Ibrahim Abushouk,3,4,∗ Sahar Mirbaha,5 and Alireza Baratloo6

1Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2Faculty of Physical Therapy, Cairo University, Cairo, Egypt
3Faculty of Medicine, Ain Shams University, Cairo, Egypt
4NovaMed Medical Research Association, Cairo, Egypt
5Department of Emergency Medicine, Imam Hosein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

∗Corresponding author: Abdelrahman Ibrahim Abushouk, Ain Shams University, Postal code 11566, Cairo, Egypt. Tel: +20-1014295780, E-mail: abdelrahman.abushouk@med.asu.edu.eg

Received 2016 October 07; Accepted 2017 February 15.

Abstract

Background: Atypical femoral fracture (AFF) is a tensile fracture with unique radiographic and clinical features that differ from ordinary osteoporotic femoral fractures. Denosumab is a novel agent that inhibits osteoclastic activity, reducing bone resorption. Within the past few years, several case reports indicated that patients on denosumab prescription are at risk of AFF. The purpose of this review was to discuss the current evidence regarding this association and draw recommendations for clinicians about the use of denosumab in osteoporotic patients, until such evidence is established in future studies.

Methods: A computer search of Medline (through PubMed and OVID search) engines was conducted using the following keywords: “Denosumab” and “atypical femoral fractures”. Furthermore, we reviewed the reference list of included studies for further citations.

Results: We identified 9 case reports, 5 clinical trials, and 1 prospective observational study that have reported data regarding the incidence of AFF in patients on denosumab prescription.

Conclusions: Denosumab is an effective treatment for osteoporosis; however, there is a growing number of reports regarding its association with AFF. Causality needs verification in future observational and interventional studies; meanwhile, screening for AFF in patients receiving denosumab and reevaluating the optimal antiresorptive therapy in osteoporotic patients is recommended.

Keywords: Atypical Femoral Fractures, Denosumab, Osteoporosis

1. Background

Atypical femoral fracture (AFF) is a tensile fracture characterized by unique radiographic and clinical features that differentiate it from ordinary osteoporotic femoral fractures (1). The term “atypical” was assigned in 1978 by Barcsa et al. (2) to describe fatigue fractures. After that, several case reports, case series, and registry-based studies reported the occurrence of AFF (3, 4). The American society for bones and mineral research (ASBMR) held a meeting to solve questions related to this problem (5) by reviewing the literature on AFF from 1990 to 2010 to set a case definition for AFF with specific criteria that differentiate it from other types of femoral fractures. These criteria act as a guide for subsequent studies to report any finding with the same definition criteria, as illustrated in Table 1. All major criteria are required to fulfill the case definition for AFF, while none of the minor criteria are required, but sometimes they have been associated with AFF (1).

The proximal one-third of the femoral shaft is the most common site for AFF. These fractures represent 17% to 29% of subtrochanteric and diaphyseal fractures (6). They also represent 0.4% of all fractures, occurring in patients on Bisphosphonates (BPs) therapy (6, 7).

Denosumab is an FDA approved antiresorptive agent, available for osteoporosis treatment and fracture prevention (8). It inhibits bone resorption and increases cortical and trabecular bone mass and strength. It acts through blocking the effect of the receptor activator of nuclear factor KB ligand (RANKL), preventing its binding to receptors and decreasing bone resorption by osteoclasts. Denosumab is administrated subcutaneously every 6 months at a dosage of 60 mg to treat osteoporosis (9, 10). In studies comparing denosumab and BPs, denosumab was proven to have a more potent and a long lasting effect than BPs, particularly in postmenopausal osteoporotic females (11,
Table 1. ASBMR Major and Minor Criteria for Diagnosis of AFF

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>The fracture is associated with no or minimal trauma, as in a fall from a standing height or less.</td>
</tr>
<tr>
<td>2</td>
<td>The fracture is noncomminuted or minimally comminuted.</td>
</tr>
<tr>
<td>3</td>
<td>Complete fractures that extend through both cortices and may be associated with a medial spike, whereas incomplete fractures involve only the lateral cortex.</td>
</tr>
<tr>
<td>4</td>
<td>The fracture line originates at the lateral cortex to be transverse in its orientation, or it may be oblique as it progresses medially across the femur.</td>
</tr>
<tr>
<td>5</td>
<td>Located anywhere along the femoral diaphysis from the area just below the lesser trochanter, to the supracondylar flare of the distal femoral metaphysis.</td>
</tr>
<tr>
<td>Minor</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Generalized increase in cortical thickness of the femoral diaphysis.</td>
</tr>
<tr>
<td>2</td>
<td>Unilateral or bilateral prodromal symptoms, such as dull or aching pain in the groin or thigh.</td>
</tr>
<tr>
<td>3</td>
<td>Delayed healing.</td>
</tr>
<tr>
<td>4</td>
<td>Usage of pharmaceutical agents such as BPs, glucocorticoids (GCs), proton pump inhibitors.</td>
</tr>
<tr>
<td>5</td>
<td>Presence of comorbid conditions such as vitamin D deficiency, Rheumatoid Arthritis, hypophosphatasia.</td>
</tr>
</tbody>
</table>

Recently, several case reports have been published on the occurrence of AFFs in denosumab treated patients (13-15). The exact incidence of AFF is still unknown for the general population without osteoporosis who are not exposed to antiresorptive drugs, and for osteoporotic patients exposed to antiresorptive drugs. These missing data may lead to misinterpreting the association between AFF and its causality (1). Are these fractures related to antiresorptive drugs such as denosumab or are they generally attributed to baseline conditions as osteoporosis? The present review aimed at discussing the current evidence on the association between denosumab and the incidence of AFF and providing recommendations for clinicians to use denosumab in osteoporotic patients until such evidence is established in future studies.

2. Methods

We searched Medline database through PubMed and OVID search engines during July 2016 for English original articles reporting on the occurrence of AFF in denosumab treated patients. We used the following keywords: “Denosumab” and “Atypical femoral fracture”.

Two authors (Ismail A. and Bekhet A.H.) independently reviewed the titles and abstracts of search results; and if the abstract was not conclusive, the full text was obtained to make a cutoff decision. Disagreements were resolved by a third reviewer. We also conducted a manual search for articles cited in included studies.

3. Results

Our search of PubMed and OVID databases, using the key words “(atypical femoral fractures) AND (denosumab)”, retrieved 116 unique records. Fifteen articles (9 case reports, 5 clinical trials, and 1 observational study) met the inclusion criteria and were included in this scoping review (Figure 1).

3.1. Case Reports

Nine case reports were published about the occurrence of AFF in patients receiving denosumab from 2013 to 2016. Table 2 summarizes the main characteristics of these reports and the criteria of their patients.

3.2. Observational Studies

One single-arm prospective observational study by Silverman et al. 2015, concluded that no cases of AFF were reported over 24 months in 935 postmenopausal females who were enrolled within 4 weeks after the first subcutaneous injection of denosumab (14).
Table 2. The Findings of the Published Case Reports About the Occurrence of AFF in Denosumab Treated Patients

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Age, y</th>
<th>Sex (M/F)</th>
<th>Denosumab Dose, mg</th>
<th>Concurrent Illness</th>
<th>Other Antiresorptive Drugs</th>
<th>Fracture</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Villiers, Clark, Jeswani, Webster, and Hepburn, 2013</td>
<td>78</td>
<td>F</td>
<td>3</td>
<td>Rheumatoid arthritis</td>
<td>Alendronate and strontium</td>
<td>Unilateral non-committed fracture with medial spike</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Paparodis, Buehring, Pelley, and Binkley, 2013</td>
<td>81</td>
<td>F</td>
<td>1</td>
<td>Chronic kidney disease and Hyper-parathyroidism</td>
<td>Estrogen therapy</td>
<td>Unilateral transverse subtrochanteric</td>
<td>treated conservatively with non-weight bearing</td>
</tr>
<tr>
<td>Thompson, Armstrong, and Heyburn, 2014</td>
<td>59</td>
<td>F</td>
<td>1</td>
<td>Rheumatoid arthritis</td>
<td>Alendronate</td>
<td>Bilateral, with a three months interval</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Drampalos, Skarpas, Barbounakis, and Michos, 2014</td>
<td>73</td>
<td>F</td>
<td>1 dose before 1st fracture then 2 doses before 2nd fracture</td>
<td>-</td>
<td>Alendronate</td>
<td>Bilateral transverse femoral shaft fractures, with a one year interval</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Schilcher and Aspenberg, 2014</td>
<td>83</td>
<td>F</td>
<td>3 doses before 2nd fracture</td>
<td>-</td>
<td>Alendronate and zoledronate</td>
<td>Bilateral (1st complete and the 2nd incomplete)</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Khow and Yong, 2015</td>
<td>72</td>
<td>F</td>
<td>3</td>
<td>Chronic obstructive pulmonary disease</td>
<td>Alendronate and strontium</td>
<td>Unilateral subtrochanteric fracture</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Ramchand, Chiang, Zebaze, and Seeman, 2016</td>
<td>82</td>
<td>F</td>
<td>1</td>
<td>Diabetes mellitus</td>
<td>Prior bisphosphonates therapy</td>
<td>bilateral recurrent incomplete</td>
<td>Bilateral internal fixation</td>
</tr>
<tr>
<td>Selga, Nunez, Minguell, Lalanza, and Garrido, 2016</td>
<td>62</td>
<td>F</td>
<td>5</td>
<td>-</td>
<td>Alendronate, risedronate, and ibandronate</td>
<td>Bilateral Simultaneous</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
<tr>
<td>Ohnaru, 2016</td>
<td>62</td>
<td>F</td>
<td>15 (120 mg every 4 weeks)</td>
<td>Breast cancer</td>
<td>Zolendronate</td>
<td>Unilateral subtrochanteric fracture</td>
<td>Anterograde interlocked femoral nailing with reaming</td>
</tr>
</tbody>
</table>

3.3. Clinical Trials

The FREEDOM trial, an open label study of 4500 postmenopausal females, had a 7-year extended program to evaluate the effect of denosumab subcutaneous injection every 6 months on bone mineral density of the enrolled participants. The results of the study revealed that AFF is a rare occurrence with denosumab prolonged use (1 to 10: 10,000 patients on denosumab 60 mg for 30 months) (16, 17).

Other 4 clinical trials (an open label trial by Recknor et al. 2013) reported no cases of AFF (n = 0) over a 6- month period (18). The other three double blinded trials (Orwoll et al. 2012; McClung et al. 2013; and Freemantle et al. 2012) reported no cases of AFF in postmenopausal females receiving denosumab (n = 0) over 1, 2, and 4 years, respectively (19-21).

4. Discussion

Due to its antiresorptive activity, a growing number of case reports suggests an association between denosumab and AFFs, despite its rarity. Some common features exist among the discussed case reports in this review. In all of them, the patients were elderly females. Five cases of bilateral AFF have been reported (One case of simultaneous bilateral fractures (22) and 4 cases in which the 2 fractures occurred separately (13, 23-25)).

The current evidence is primarily limited to case reports, which are highly confounded by the former use of BPs and glucocorticoids, which have an established relationship with AFF (in all 9 reports except 1 case by Paparodis et al. 2013 (26)). Uncertainty is further extended by the notion that 4 of these cases occurred after receiving only 1 dose of denosumab (13, 23, 24, 26). This finding favors the theory that AFF results from fresh microcracks, for which
remodeling is impaired, not the disturbance of bone tissue properties.

Data from the published FREEDOM trial revealed that the benefits of denosumab in osteoporosis outbalance the risk of the rare occurrence of AFF. It decreased the risk of vertebral fractures by 68%, nonvertebral fractures by 26%, and hip fractures by 40% (16, 17). Intriguingly, no cases of AFF have been reported in oncology studies, in which denosumab is used at a higher dosage than that of osteoporosis treatment trials. However, only 1 case report by Ohnaru et al. (27) reported a case of AFF in a breast cancer patient receiving denosumab for bone metastasis. An advisory has warned about severe hypocalcemia, reported at such high doses (28). Further epidemiological studies with larger sample size and radiographic adjudication are required to verify the association between denosumab and AFF.

The exact pathophysiology of AFF in patients receiving antiresorptive drugs including denosumab has not yet been established. A major hypothesis is that antiresorptive drugs inhibit bone turnover leading to accumulation of microdamage and increasing the risk of AFF (1). Also, such inhibition leads to accumulation of advanced glycation end-products in collagen-B fibers, leading to increased bone brittleness (29). Moreover, the antiangiogenic properties of these drugs do not allow the repair of such accumulating damage (30). For denosumab, it specifically binds to RANKL on osteoclast precursors, suppressing the formation of new osteoclasts and inhibiting the activity of the existing cells. Therefore, bone matrix is not replaced and undergoes secondary mineralization (a form of premature bone aging), reducing its ability to deform during loading to absorb energy. The small change of normal bone mineralization density distribution (BMDD) impairs the ability of bone to resist cracks, which is directly proportional to the bone stiffness ratio (13).

It would be valuable to develop a screening tool to identify patients at risk of AFF and count them ineligible for antiresorptive drug therapy. The correlation between tissue mineralization density and the level of circulating cross-linking collagen-1 and RANKL on osteoclast precursors, suppressing the formation of new osteoclasts and inhibiting the activity of the existing cells. Therefore, bone matrix is not replaced and undergoes secondary mineralization (a form of premature bone aging), reducing its ability to deform during loading to absorb energy. The small change of normal bone mineralization density distribution (BMDD) impairs the ability of bone to resist cracks, which is directly proportional to the bone stiffness ratio (13).

Despite lack of evidence, it is recommended that once these fractures are suspected, a plain x-ray imaging for 3 months. If no healing occurs or the fracture line progressed, operative management should be considered (32).

It is plausible that once these fractures occur, antiresorptive medications should be stopped (33). Other options to manage osteoporosis include monoclonal antisclerostin antibodies, which enhance bone formation (34). Some authors suggested shifting to a weaker antiresorptive agent such as raloxifene, which increases bone toughness through increasing its water content without affecting tissue mineral composition (13). Chiang et al. reported that teriparatide prescription improves the healing of AFF; however, this finding needs to be further verified (35). Further randomized clinical trials are needed to verify the safety and efficacy of these strategies in detection and treatment of AFF.

4.1. Conclusions

Denosumab is an effective antiresorptive agent; however, a growing number of reports indicates its possible association with AFF. Causality needs verification in future observational and interventional studies; meanwhile, screening for AFF in patients receiving denosumab and reevaluating the optimal antiresorptive therapy in osteoporotic patients is recommended.

Footnotes

Competing Interests: None of the authors has any competing interest to declare.

Funding/Support: None.

References


Ismail A et al. Trauma Mon. 2018; 23(1):e42869.

Ismail A et al.